These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 15257864)

  • 1. Compelling drug indications in diabetic and nondiabetic nephropathy.
    Ritz E; Dikow R; Zeier M
    Curr Hypertens Rep; 2004 Aug; 6(4):293-9. PubMed ID: 15257864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of calcium antagonists in chronic kidney disease.
    Gashti CN; Bakris GL
    Curr Opin Nephrol Hypertens; 2004 Mar; 13(2):155-61. PubMed ID: 15202609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A; Ribstein J
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy.
    Ruilope LM
    J Hypertens Suppl; 1995 Aug; 13(2):S91-3. PubMed ID: 8576796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease.
    Andersen NH; Mogensen CE
    Curr Hypertens Rep; 2004 Oct; 6(5):369-76. PubMed ID: 15341690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valsartan and the kidney: review of preclinical and clinical data.
    Ruilope LM
    Adv Ther; 2001; 18(2):57-66. PubMed ID: 11446269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 18. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
    Sarafidis PA; Ruilope LM
    Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.